Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
Acesion, Addendum, adware, affirmative, AI, anchored, ANCOVA, artificial, authentication, automated, bifurcation, Black, capture, CASL, CCPA, chosen, Circulation, clarification, clarified, Colorado, comment, concurred, conjunction, Connecticut, CPRA, credential, deceptive, deep, defense, dialogue, diligence, disaggregated, disaster, domain, email, embedded, encryption, expert, Extortion, facilitate, facilitated, fake, FASB, feature, Featured, Florida, forensic, gather, Gaza, hardware, harvesting, hosting, hourly, importantly, inconsistent, infer, inhibitor, inquiry, instrument, Interagency, IRS, ITT, Lancet, leaked, lieu, manual, marked, misrepresentative, monumental, nadir, necessitate, notified, notify, NS, offline, online, PA, path, percent, Pharma, Philadelphia, PIPEDA, PIPL, pretax, reconciling, reformat, reformatted, reiterated, resubmission, revealed, RTF, Science, sensitive, sensitivity, server, simultaneously, SIP, SK, sNDA, software, sterling, stuffing, supine, threat, Treasury, UK, undermine, undertaken, underwent, underwritten, unemployment, unfair, unstable, variance, vendor, Vice, Virginia, VP, VR, wiretapping, written
Filing tables
Filing exhibits
MIST similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-231347, 333-236971, 333-254838, 333-271522 and 333-263807) and on Form S-3 (Nos. 333-261049, 333-257404, 333-248198 and 333-271949) of Milestone Pharmaceuticals Inc. of our report dated March 21, 2024 relating to the consolidated financial statements, which appears in Milestone Pharmaceuticals Inc.’s Annual Report on Form 10-K for the year ended December 31, 2023.